Haemophilia Trial, Recruiting NCT06550882 Sponsor: Takeda Condition: Haemophilia
Back to Haemophilia

Haemophilia Trial, Recruiting

NCT06550882
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Acquired Hemophilia A (a condition where the body's immune system attacks its own clotting proteins, making it hard to stop bleeding).
  • People whose doctor has determined they have a medical need to receive the treatment called Obizur.
  • People who are 18 years of age or older at the time they start Obizur treatment.
  • People who have agreed to take part in the study and have signed a consent form.

Who may not be able to join:

  • People who have a known allergy or sensitivity to any of the ingredients in Obizur.
  • People who have Congenital Hemophilia A with Inhibitors (a hereditary bleeding disorder that is different from Acquired Hemophilia A).
  • People for whom Obizur is listed as unsuitable or unsafe according to the official product guidelines (confirm with trial site).
  • People who have taken part in another clinical trial involving a medicine or medical device within the 30 days before enrolling, or who plan to join another such trial while this study is ongoing.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Study Director, Takeda

Phone: +1-877-825-3327

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
22 July 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Number of Participants With Adverse Events (AEs), Causality to AEs, Serious AEs (SAEs) and AEs of Special Interest (AESI); Number of Participants With Expected/Unexpected AEs and SAEs; Number of Participants With Adverse Drug Reactions (ADRs), Unexpected ADRs, Serious ADRs, Expected SADRs and Unexpected SADRs; Number of Participants With Special Situation Report (SSR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov